• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will New Desmoid Tumor Data Change Immunome (IMNM) Stock Narrative

    Simply Wall St·10/27/2026 14:16:54
    Listen to the news
    • Immunome recently reported new clinical data from the RINGSIDE trial at the 2026 ESMO Congress, showing that desmoid tumor patients on varegacestat reported improved symptoms and physical function alongside previously disclosed objective response and progression free survival outcomes.
    • The combination of patient reported outcome benefits and an already accepted FDA NDA for varegacestat may position Immunome to move from a pure R&D story toward its first commercial product in desmoid tumors.
    • We will now look at how Immunome’s investment narrative could shift given the stronger patient reported outcomes for varegacestat in desmoid tumors.

    Scan beyond Immunome and look at other late-stage, clinically focused biotech opportunities using the hand picked 21 high quality undiscovered gems, which are often missed in broader healthcare indices.

    Immunome Investment Narrative Recap

    To own Immunome, you need to believe varegacestat can move from a single late stage program to a real commercial pillar and fund a broader oncology pipeline. The big near term catalyst is the FDA decision on the desmoid tumor NDA, which now sits against RINGSIDE data that include symptom and physical function gains from the 2026 ESMO update.

    The largest risk is still binary. A delay, restrictive label or rejection would leave Immunome with no product revenue and ongoing R&D heavy losses. If approved, real world adoption and pricing in a relatively small, still under treated desmoid market will determine how the business moves toward a more balanced operating profile.

    The NDA acceptance for varegacestat with an April 28, 2027 PDUFA date is the announcement that matters most in light of the new RINGSIDE quality of life readout. The fresh ESMO data do not change that timeline, but they provide additional detail on how the drug might affect daily life for desmoid patients if approved.

    For shareholders, that NDA milestone defines the path from a zero revenue biotech with a US$2.0b market cap and heavy losses toward a potential first product. Around that, the early stage ADC and radioligand programs, plus the forecasted high revenue growth, remain secondary but important factors for potential future catalysts and risk management.

    Immunome Long Term Forecasts In Context

    Immunome's narrative projects US$306.2 million revenue and US$52.8 million earnings by 2029. This requires revenue to build from a zero base and an earnings increase of about US$307.1 million from a loss of US$254.3 million today.

    Uncover why Immunome's fair value indicates a 103% potential upside to its current price that may not last much longer.

    NasdaqCM:IMNM 1-Year Stock Price Chart
    NasdaqCM:IMNM 1-Year Stock Price Chart

    Exploring Other Perspectives

    You are seeing the friendliest bearish twist around Immunome in the revenue line. The lowest analysts were pencilling in only US$113.8 million of sales and US$19.6 million of earnings by 2029, far below consensus, on the view that desmoid uptake might stay muted. Fresh RINGSIDE quality of life data could eventually lead that story to evolve, so treat these pre news forecasts as moving parts and explore several viewpoints before you decide how much risk you are comfortable taking.

    Explore 2 other Immunome fair value estimates, including one that suggests it could be worth just $35.33.

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view.

    Looking For More Investment Ideas Beyond Immunome?

    Once you have a view on Immunome, it can help to set it alongside a few very different opportunities so you can compare risk, balance sheet strength, and potential income in one place.